Name | Role | Date | Shares | Price | Value |
---|---|---|---|---|---|
Karen Akinsanya | President of RD Therapeutics | 2025-04-14 | 13,378 | $3.22 | $43.08kBuy |
Karen Akinsanya | President of RD Therapeutics | 2025-04-14 | 3,345 | $2.92 | $9.77kBuy |
Karen Akinsanya | President of RD Therapeutics | 2025-04-14 | 8,378 | $25.11 | $210.39kSell |
Karen Akinsanya | President of RD Therapeutics | 2025-04-14 | 5,000 | $25.11 | $125.56kSell |
Karen Akinsanya | President of RD Therapeutics | 2025-04-14 | 3,345 | $25.00 | $83.63kSell |
Jenny Herman | SVP Controller | 2025-03-06 | 666 | $21.11 | $14.06kSell |
Geoffrey Craig Porges | EVP CFO | 2025-03-03 | 5,491 | $21.76 | $119.48kSell |
Yvonne Tran | EVP CLO CPO | 2025-02-18 | 3,902 | $28.00 | $109.26kSell |
Yvonne Tran | EVP CLO CPO | 2025-02-18 | 3,902 | $4.34 | $16.93kBuy |
Jenny Herman | SVP Controller | 2025-02-11 | 859 | $24.43 | $20.99kSell |
Name | Hold | Shares | Value | Type |
---|---|---|---|---|
Blackrock Inc | 12.04% | 8,797,072 | $230.40M | Institution |
Gates Foundation Trust | 9.56% | 6,981,664 | $182.85M | Institution |
Melinda Gates Foundation Trust Bill | 9.56% | 6,981,664 | $182.85M | Insider |
Vanguard Group Inc | 9.05% | 6,612,390 | $173.18M | Institution |
David E. Shaw | 8.48% | 6,196,609 | $162.29M | Insider |
Rubric Capital Management LP | 6.85% | 5,000,000 | $130.95M | Institution |
Sumitomo Mitsui Trust Group Inc | 4.81% | 3,510,518 | $91.94M | Institution |
Nikko Asset Management Americas Inc | 3.37% | 2,464,911 | $64.56M | Institution |
State Street Corp | 3.17% | 2,316,601 | $60.67M | Institution |
Massachusetts Financial Services Co | 3.12% | 2,279,313 | $59.70M | Institution |